A selective RAR gamma antagonist relieves osteoarthritis like knee pain in the rodent  by Chambers, M.G. et al.
Table 1
MIA Pain Measurements (Saline-MIA) (g)
Treatment Day9
Vehicle 21.940.55
0.1mg/kg LY2813631 21.140.72
0.3mg/kg LY2813631 18.290.25*
1mg/kg LY2813631 16.870.75*
3mg/kg LY2813631 13.780.69*
0mg/kg LY2813631 12.010.51*
MeanSEM n¼5
Table 2
NSAID non-responding MIA Pain Measurements (Saline-MIA) (g)
Treatment Day 43
Vehicle 52.081.14
5mg/kg diclofenac (NSAID) 521.17
1mg/kg LY2813631 45.640.88*
3mg/kg LY2813631 44.641.57*
MeanSEM n¼6
Table 3
MT Pain Measurements (Contra-lateral non surgical-surgical)(g)
Treatment 13 days 17 days
Vehicle 48.690.85 47.40.9
10mg/kg LY2813631 43.760.76* 38.140.94*
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condyle, or tibial plateau, crescent sign)
 MRI: diagnosis of ON (based on: well-deﬁned margin
surrounding a focus of fat-like or ﬂuid-like or low signal +/-
surrounding edema, change in contour of the femoral head,
femoral/tibial condyle, or tibial plateau)
Histopathologic evidence (if available):
 Evidence of ON at surgery histopathologic/gross specimen
report. Histopathology must have corresponded to radio-
graphic evidence.
RPOA
Radiologic evidence:
 Required availability of baseline comparison ﬁlm(s)
 Initial radiograph: OA Kellgren-Lawrence (K-L) grade of 0 to 3
in the replaced joint
 Follow-up radiograph:
- Focal joint space narrowing  50% or  2 mm per year
- Flattening of the femoral head
- Flattening of the femoral/tibial condyle and/or tibial plateau
Histopathologic evidence (if available):
 Histopathology consistent with totality of clinical and radio-
graphic ﬁndings
 If ON present, evidence of focal ON only
RPOA sub-categorization
 Type I: Focal joint space narrowing > 50% or > 2 mm per year
 Type II: Rapid and aggressive destruction of bone, with or
without subluxation of the joint
One hundred nine joints (94 patients, including 62 knees, 43 hips, 3
shoulders, and 1 lumbar spine) were adjudicated with the following
results: 72 NPOA, 18 RPOA, 14 II, 0 ON, and 0 RPOA+ON. Five cases were
considered not appropriate for review because of revisions of joint
replacements or repair of lumbar device failure. Among the 18 RPOA, 7
(4 knees and 3 hips) were Type I and 11 (4 knees and 7 hips) were Type
II. The adjudicators agreed unanimously on 81% of the cases. All 18 cases
that had an original radiologic diagnosis of ON in the Clinical Centers
were adjudicated by the AC as 9 RPOA, 8 NPOA, and 1 II. All 72 NPOA
cases and 1 RPOA were assessed as “not related" to study drug, and 17
RPOA cases were assessed as “possibly related".
Conclusions: RPOA may occur in association with fulranumab use and
is a safety signal. Among 109 cases reviewed, 18 were adjudicated as
RPOA, all of which occurred in fulranumab-treated patients. ONwas not
identiﬁed as a safety signal in the fulranumab studies.
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A SELECTIVE RAR GAMMA ANTAGONIST RELIEVES OSTEOARTHRITIS
LIKE KNEE PAIN IN THE RODENT
M.G. Chambers y, J. Oskins y, C. Lin y, T.J. Bleisch z, B.H. Norman z. y Eli Lilly
Musculoskeletal Drug Hunting Team, Indianapolis, IN, USA; z Eli Lilly
Discovery Chemistry, Indianapolis, IN, USA
Purpose: Osteoarthritis (OA) is a chronic debilitating joint disease with
resulting pain and cartilage degradation in the affected joint. It is known
that levels of retinoids are increased in both plasma and synovial ﬂuid of
patients with OA. We therefore hypothesize that retinoic acid receptor
gamma (RARg) antagonists may be beneﬁcial in the treatment of OA
pain. As antagonism of the RARa receptor has been linked to testicular
toxicity we chose to target RARg speciﬁc antagonism as there was no
reported toxicity associated with this receptor. We conﬁrmed that an
RARg agonist can induce knee pain when given intra-articularly. Alsoa selective RARg agonist when co-treated reversed the pain efﬁcacy of
the selective antagonist, indicating the critical role for RARg in medi-
ating pain efﬁcacy. Accordingly, we identiﬁed a highly selective RARg
antagonist (LY2813631) and tested its affect on pain in three models of
OA- like knee pain, the rat monoiodoacetate (MIA) model, the nonste-
roidal anti-inﬂammatory drug (NSAID) non-responding MIA model and
the rat meniscal tear (MT) model.
Methods: In the rat MIA model injection of MIA (0.3mg) into the right
knee joint produces an acute inﬂammatory insult which develops into
chronic degeneration of the joint tissues. In contrast, in the MT model
rapidly progressing degenerative changes in the joint, including carti-
lage ﬁbrillation and erosion and osteophyte formation occur when the
medial collateral ligament and meniscus of the right knee are trans-
ected. The pain resulting from the joint injury in both models can be
measured via differential weight bearing of the hind legs using an
incapacitance tester. To test whether RARg antagonist (LY2813631)
could reduce pain in these models compound was dosed after pain
induction and differential weight bearing measured. This was done as
a dose response in the standard MIA model 12 days post MIA injection.
In the MT model LY2813631 was assessed for pain efﬁcacy at a single
dose 13 and 17 days post MT surgery. LY2813631 was also tested in
a version of the MIA model that does not show pain relief with non
steroidal anti-inﬂammatory drugs (NSAIDs) at 43 days post MIA (1mg)
injection.
Results: MIA model- At 12 days post MIA injection RARg antagonist
(LY2813631) signiﬁcantly inhibited pain at doses of 0.3, 1, 3 and 10mg/
kg test (*p<0.05 table 1)NSAID non-respondingMIAmodel- At 43 day post MIA injection RARg
antagonist (LY2813631) signiﬁcantly inhibited pain in the NSAID non-
responding MIA model (*p<0.05 table 2). As expected the NSAID
diclofenac did not show efﬁcacy in this model.MT model- At 13 and 17 days post MIA injection RARg antagonist
(LY2813631) signiﬁcantly inhibited pain (*p<0.05 table 3)Conclusions: RARg antagonist (LY2813631) was effective at reducing in
three different models of osteoarthritic like knee pain: the MIA model,
the NSAID non-responding MIA model, and the MT model. Therefore
such a selective agent could provide therapeutic beneﬁt when tested in
clinical studies without some of the obvious deleterious effects of a non
speciﬁc retinoid acid receptor antagonist.
MeanSEM n¼6
